Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Other financing activities (2017 - 2021)

Spero Therapeutics (SPRO) has disclosed Other financing activities for 5 consecutive years, with -$163000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Other financing activities fell 143.7% year-over-year to -$163000.0, compared with a TTM value of $102000.0 through Dec 2022, down 58.87%, and an annual FY2021 reading of $248000.0, down 73.98% over the prior year.
  • Other financing activities was -$163000.0 for Q4 2021 at Spero Therapeutics, down from $265000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $3.1 million in Q4 2017 and bottomed at -$753000.0 in Q2 2018.
  • Average Other financing activities over 5 years is $236055.6, with a median of $94000.0 recorded in 2019.
  • The sharpest move saw Other financing activities plummeted 1830.77% in 2018, then skyrocketed 2100.0% in 2020.
  • Year by year, Other financing activities stood at $3.1 million in 2017, then crashed by 122.17% to -$680000.0 in 2018, then soared by 111.62% to $79000.0 in 2019, then soared by 372.15% to $373000.0 in 2020, then plummeted by 143.7% to -$163000.0 in 2021.
  • Business Quant data shows Other financing activities for SPRO at -$163000.0 in Q4 2021, $265000.0 in Q3 2021, and $109000.0 in Q2 2021.